Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates

Biochemical Pharmacology

Volumn 60, Issue 1, 2000, Pages 83-90

  Astriab Fisher, Anna ^a   Sergueev, Dimitri S ^b   Fisher, Michael ^a   Ramsay Shaw, Barbara ^b   Juliano, Rudolph L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Antisense; Drug delivery; Drug resistance

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG UPTAKE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENE PRODUCTS, TAT; HUMANS; MICE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; PEPTIDES; TRANSFECTION;

EID: 0034012647     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00310-5     Document Type: Article

References (36)

1. Crooke S.T. An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev. 8:1998;115-122.
2. Agrawal S. Antisense oligonucleotides Towards clinical trials . Trends Biotechnol. 14:1996;376-378.
3. Wagner R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 372:1994;333-335.
4. Stein C.A., Cheng Y.-C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science. 261:1993;1004-1012.
5. Flanagan W.M. Antisense comes of age. Cancer Metastasis Rev. 17:1998;169-176.
6. Ho P.T., Parkinson D.R. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol. 24:1997;187-202.
7. Licht T., Pastan I., Gottesman M., Herrmann F. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol. 69:1994;159-171.
8. Bradley G., Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 13:1994;223-233.
9. Chabner B.A., Wilson W. Reversal of multidrug resistance. J Clin Oncol. 9:1991;4-6.
10. Dalton W.S. Is P-glycoprotein a potential target for reversing clinical drug resistance? Curr Opin Oncol. 6:1994;595-600.
11. Dalton W.S., Crowley J.J., Salmon S.S., Grogan T.M., Laufman L.R., Weiss G.R., Bonnet J.D. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma A Southwest Oncology Group Study . Cancer. 75:1995;815-820.
12. Scanlon K.J., Ishida H., Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug resistant phenotype. Proc Natl Acad Sci USA. 91:1994;11123-11127.
13. Kobayashi H., Dorai T., Holland J.F., Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 54:1994;1271-1275.
14. Alahari S.K., Dean N.M., Fisher M.H., DeLong R., Manoharan M., Tivel K.L., Juliano R.L. Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol. 50:1996;808-819.
15. Alahari S.K., DeLong R., Fisher M.H., Dean N.M., Viliet P., Juliano R.L. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther. 286:1998;419-428.
16. Corrias M.V., Tonini G.P. An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res. 12:1992;1431-1438.
17. Efferth T., Volm M. Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology. 50:1993;303-308.
18. Cucco C., Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 56:1996;4332-4337.
19. Juliano R.L., Alahari S., Yoo H., Kole R., Cho M. Antisense pharmacodynamics Critical issues in the transport and delivery of antisense oligonucleotides . Pharm Res. 16:1999;494-502.
20. Bennett C.F., Chiang M.Y., Chan H., Shoemaker J.E., Mirabelli C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 41:1992;1023-1033.
21. DeLong R.K., Yoo H., Alahari S.K., Fisher M., Short S.M., Kang S.H., Kole R., Janout V., Regan S.L., Juliano R.L. Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. Nucleic Acids Res. 27:1999;3334-3341.
22. Lewis J.G., Lin K.-Y., Kothavale A., Flanagan W.M., Matteucci M.D., DePrince R.B., Mook R.A. Jr, Hendren R.W., Wagner R.W. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA. 93:1996;3176-3181.
23. Falwell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., Barsoum J. Tat mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA. 91:1994;664-668.
24. Kim D.T., Mitchell D.J., Brockstedt D.G., Fong L., Nolan G.P., Fathman C.G., Engleman E.G., Rothbard J.B. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol. 159:1997;1666-1668.
25. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem. 271:1996;18188-18193.
26. Aldrian-Herrada G., Desarmenien M.G., Orcel H., Boissin-Agasse L., Mery J., Brugidou J., Rabie A. A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucleic Acids Res. 26:1998;4910-4916.
27. Pooga M., Soomets U., Hallbrink M., Valkna A., Saar K., Rezaei K., Kahl U., Hao J.X., Xu X.J., Wiesenfeld-Hallin Z., Hokfelt T., Bartfai T., Langel U. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol. 16:1998;857-861.
28. Chaloin L., Vidal P., Lory P., Mery J., Lautredou N., Divita G., Heitz F. Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. Biochem Biophys Res Commun. 243:1998;601-608.
29. Kane S.E., Reinhard D.H., Fordis C.M., Pastan I., Gottesman M.M. A new vector using the human multidrug resistance gene as a selectable marker enables overexpression of foreign genes in eukaryotic cells. Gene. 84:1989;439-446.
30. Zuckerman R., Corey D., Schultz P. Efficient methods for attachment of thiol specific probes to the 3′-ends of synthetic oligodeoxyribonucleotides. Nucleic Acids Res. 15:1987;5305-5321.
31. Vives E., Lebleu B. Selective coupling of a highly basic peptide to an oligonucleotide. Tetrahedron Lett. 38:1997;1183-1186.
32. Riddle P.W., Blakeley R.L., Zerner B. Reassessment of Ellman's reagent. Methods Enzymol. 91:1983;49-60.
33. Vives E., Brodin P., Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 272:1997;16010-16017.
34. Yoo H., Sazani P., Juliano R.L. PAMAM dendrimers as delivery agents for antisense oligonucleotides. Pharm Res. 16:1999;1799-1804.
35. Kip1 induces cell migration . Nat Med. 4:1998;1449-1452.
36. Troy CM, Stefinis L, Prochiantz A, Greene LA and Shelanski ML, The contrasting roles of ICE family proteases and interleukin-1β in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc Natl Acad Sci USA 93: 5635-5640, 1996.